Opera Limited
OPRAOpera Limited's earnings have outrun its stock. EPS grew +32.2% in a year against a −2.1% price move.
The sharpest disagreement: annual EPS moved +32.2% against a −2.1% price move — the market has not yet caught up with the delivery.
The price is in a confirmed uptrend (1 weeks in) while the P/E sits at the 37th percentile of its own 4-year range. Underneath, the last four quarters read improving — profit +0.0% year on year, and 88% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Opera Limited trades at $18.4, in a confirmed uptrend and 1 weeks into that stage. That is +11.6% against its own 200-day average. It sits at 76% of a 52-week range of $12 to $20. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (3 weeks and counting).
Today the stock is in a confirmed uptrend — week 1 of stage 2. At $18.4 it trades +11.6% versus its 200-day average and sits at 76% of its 52-week range ($12–$20).
Against the market, two honest reads. Cumulative: over the last 8.1 years the stock moved +60% while the S&P 500 moved +166% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (3 weeks and counting; last ahead the week of 2026-08-28) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Opera Limited trades at 13.4× P/E, mid-range by its own standards (37th percentile). Its long-run median P/E is 15.0×, measured across 3.7 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 13.4× is mid-range by its own standards (37th percentile), against a long-run median of 15.0× measured over 3.7 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +32.2% against a −2.1% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 3y, of the +12.0%/yr price move, ~+17.3%/yr came from earnings growth and ~−5.3 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Opera Limited reads as turning around on its fundamental arc. Turning around — profit growth swung from −43.8% at the trough to +33.3% off a 3-quarter-old trough, ROCE holding at 10.3%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +27.1% | +22.7% | — | — |
| Profit | +37.5% | +76.5% | — | — |
| EPS | +32.2% | +104.1% | — | — |
| Stock price | −2.1% | +12.0% | +15.2% | — |
4-Factor Sector Score
65.0/100 — rank 3 of 24 in Internet Content & Information · 81% evidence confidence
Opera Limited scores 65.0 out of 100 against the 24 companies it is compared with in Internet Content & Information, ranking 3. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 23.9 + 13.3 + 14.7 + 13.1 = 65. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Opera Limited reported $0.2 B of revenue in the Mar 26 quarter, +28.6% year on year. That is the 12th straight quarter of year-on-year growth. Over 4 years it has compounded at 25.0% a year. The last full year, FY25, came in at $0.6 B. The last four reported quarters add to $0.7 B.
FY25 revenue came in at $0.6 B (+27.1% on the year), capping 4 years at 25.0% compound. The latest quarter (Mar 26) printed $0.2 B, +28.6% year on year — the 12th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +25.2% growth against the decade's 25.0% — the current year is running in line with its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +25.0% over the last 4 quarters against +27.5%/yr over the last 8 — stabilising; TTM profit +33.3% vs −13.4%/yr — accelerating.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Opera Limited's operating margin is 16.7% in the Mar 26 quarter, +2.4 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −4.0% to 18.8%. The current quarter sits inside that band.
The latest quarter's operating margin is 16.7%, +2.4 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −4.0%–18.8%.
Why the margin moved: operating margin went +2.4 pp year on year while gross margin went −3.2 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Opera Limited earned $0.0 B of net profit in the Mar 26 quarter, +0.0% year on year. Full-year FY25 profit was $0.1 B. That is 11.1% of the quarter's revenue. The same quarter a year earlier earned $0.0 B.
Mar 26 profit was $0.0 B, +0.0% year on year. On the full year, FY25 printed $0.1 B (+37.5%).
🚨 Why profit moved: revenue contributed +28.6% and the margin +2.4 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +25.0% vs revenue +25.2%. Profit and revenue are moving roughly in step.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 88% of Opera Limited's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $0.1 B of operating cash against $0.1 B of profit. After $0.0 B of capital spending, $0.1 B was left as free cash.
FY25: operating cash of $0.1 B against reported profit of $0.1 B, leaving free cash of $0.1 B after $0.0 B of capital spending. Across the last 3 fiscal years the conversion rate is 88% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Opera Limited does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Opera Limited earns a ROE of 11% in FY25. That is up from a trough of −4% in FY21. Return on invested capital clears the cost of that capital by −0.2 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 18.0% net margin on 0.54× asset turns.
FY25 ROE is 11%, recovered from a FY21 trough of −4% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY25): 18.0% net margin × 0.54× asset turns × 1.13× balance-sheet leverage ≈ 11.0% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 10.8% − 11.0% = a −0.2 pp spread. The 11.0% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
Opera Limited paid $2.00 per share over the last four reported quarters, down 50.0% on a year ago. The most recent declaration was $0.40 for Dec 25. Against the current price of $18.4 that is a trailing yield of 10.86%, measured on dividends already paid rather than on a forecast.
Opera Limited paid $2.00 per share across the last four reported quarters, most recently $0.40 for Dec 25. That is down 50.0% against the same quarter a year earlier. Against the current price of $18.4 the trailing twelve months work out to 10.86% — trailing dividends measured against today's price, not a forward estimate.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Opera Limited carries total debt of $0.0 B against shareholder equity of $1.0 B as of Mar 26, a debt-to-equity of 0.01 — effectively unlevered. On the annual view that ratio went from 0.01 in FY21 to 0.01 in FY25. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of $0.0 B against shareholder equity of $1.0 B — a debt-to-equity of 0.01. On the annual view, debt-to-equity went from 0.01 (FY21) to 0.01 (FY25). The returns on this page are earned, not borrowed.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
No ownership or positioning reading is held for Opera Limited, so this section names the gap rather than filling it. At typical trading volumes those positions would take about 4.5 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
We hold no ownership or positioning reading for this stock, so this section says that plainly.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Opera Limited: the Z-score reads 7.74. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 7.74 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 7.74.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Match Group, Inc.MTCH | 69.5/100Favorable setup81% evidence | BREAKING OUT | 21.7/35 Revenue 2% · PAT 21.6% · OPM change 6.6 pp 83% evidence | 15.5/25 ROCE 6.9% · OPM 27.4% 76% evidence | 13.9/20 P/E 11.7× · PEG 0.4 65% evidence | 18.4/20 RS sector 28.4% · RS bench 17.7% · 1Y 13.2%8 of 12 weeks ahead 100% evidence |
| Exact sum: 21.7 + 15.5 + 13.9 + 18.4 = 69.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2EverQuote, Inc.EVER | 69.1/100Favorable setup71% evidence | BREAKING OUT | 28.2/35 Revenue 24.5% · PAT 100% · OPM change 7.5 pp 83% evidence | 14.2/25 ROCE 11.9% · OPM 12.3% 76% evidence | 11.5/20 P/E 5.2× · PEG — 15% evidence | 15.2/20 RS sector 12% · RS bench 1.3% · 1Y -8.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 28.2 + 14.2 + 11.5 + 15.2 = 69.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Opera Limitedthis pageOPRA | 65.0/100Favorable setup81% evidence | ASLEEP | 23.9/35 Revenue 23.7% · PAT 38.1% · OPM change 2.1 pp 83% evidence | 13.3/25 ROCE 3.1% · OPM 16.9% 76% evidence | 14.7/20 P/E 11.3× · PEG 0.33 65% evidence | 13.1/20 RS sector 15.6% · RS bench 6.2% · 1Y -2.1%5 of 12 weeks ahead 100% evidence |
| Exact sum: 23.9 + 13.3 + 14.7 + 13.1 = 65 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Alphabet Inc.GOOGL | 64.6/100Mixed-positive evidence85% evidence | ASLEEP | 21.4/35 Revenue 20.1% · PAT 100% · OPM change 1.6 pp 95% evidence | 20.5/25 ROCE 18.5% · OPM 34% 76% evidence | 12.8/20 P/E 17.8× · PEG 0.47 65% evidence | 9.9/20 RS sector 8% · RS bench -0.6% · 1Y 34.6%1 of 12 weeks ahead 100% evidence |
| Exact sum: 21.4 + 20.5 + 12.8 + 9.9 = 64.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Spotify Technology S.A.SPOT | 60.4/100Mixed-positive evidence77% evidence | TURNING | 21.6/35 Revenue 9% · PAT 100% · OPM change 4 pp 71% evidence | 13.6/25 ROCE 8.2% · OPM 13.7% 76% evidence | 11.1/20 P/E 29.2× · PEG 0.91 65% evidence | 14.1/20 RS sector 5.8% · RS bench -4.4% · 1Y -25.5%6 of 12 weeks ahead 100% evidence |
| Exact sum: 21.6 + 13.6 + 11.1 + 14.1 = 60.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Reddit, Inc.RDDT | 58.3/100Mixed-positive evidence75% evidence | ASLEEP | 30.6/35 Revenue 66.6% · PAT 100% · OPM change 15.2 pp 95% evidence | 14.1/25 ROCE 8.1% · OPM 28.8% 76% evidence | 9.2/20 P/E 40.4× · PEG — 15% evidence | 4.4/20 RS sector -8.1% · RS bench -17.5% · 1Y -40.4%6 of 12 weeks ahead 100% evidence |
| Exact sum: 30.6 + 14.1 + 9.2 + 4.4 = 58.3 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -8.1% and the one-year return is -40.4%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 7Nebius Group N.V.NBIS | 55.9/100Mixed-positive evidence75% evidence | ASLEEP | 27.1/35 Revenue 100% · PAT 29.8% · OPM change 75.6 pp 95% evidence | 6.3/25 ROCE -1.2% · OPM -30.2% 76% evidence | 8.5/20 P/E 1212.2× · PEG — 15% evidence | 14.0/20 RS sector 42% · RS bench 32.6% · 1Y 110.8%6 of 12 weeks ahead 100% evidence |
| Exact sum: 27.1 + 6.3 + 8.5 + 14 = 55.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Taboola.com Ltd.TBLA | 55.1/100Thin evidence · provisional58% evidence | ASLEEP | 23.6/35 Revenue 9.6% · PAT 100% · OPM change 16.4 pp 62% evidence | 12.3/25 ROCE 6% · OPM 14.9% 76% evidence | 11.1/20 P/E 8.2× · PEG — 15% evidence | 8.1/20 RS sector -2.7% · RS bench -10.9% · 1Y 8.9%5 of 12 weeks ahead 70% evidence |
| Exact sum: 23.6 + 12.3 + 11.1 + 8.1 = 55.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Meta Platforms, Inc.META | 54.6/100Mixed-positive evidence85% evidence | TURNING | 12.4/35 Revenue 27.6% · PAT -4.8% · OPM change -8.2 pp 95% evidence | 21.9/25 ROCE 22.7% · OPM 34.8% 76% evidence | 5.1/20 P/E 21× · PEG 2.81 65% evidence | 15.2/20 RS sector 9.3% · RS bench -0.6% · 1Y -13.5%2 of 12 weeks ahead 100% evidence |
| Exact sum: 12.4 + 21.9 + 5.1 + 15.2 = 54.6 · Decision use: Price leads the evidence: RS versus the benchmark is -0.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 10JOYY Inc.JOYY | 51.9/100Mixed-positive evidence81% evidence | LEADER | 10.5/35 Revenue 0.9% · PAT -86.8% · OPM change -1.2 pp 83% evidence | 10.0/25 ROCE 0.1% · OPM 1.1% 76% evidence | 14.7/20 P/E 13.5× · PEG 0.3 65% evidence | 16.7/20 RS sector 25.1% · RS bench 14.6% · 1Y 25.8%11 of 12 weeks ahead 100% evidence |
| Exact sum: 10.5 + 10 + 14.7 + 16.7 = 51.9 · Decision use: Price leads the evidence: RS versus the benchmark is 14.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 11Nextdoor Holdings, Inc.NXDR | 51.1/100Thin evidence · provisional55% evidence | BREAKING OUT | 20.2/35 Revenue 6.8% · PAT — · OPM change 25 pp 62% evidence | 4.3/25 ROCE -3.4% · OPM -24.9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 16.6/20 RS sector 29.2% · RS bench 17.8% · 1Y 7.4%11 of 12 weeks ahead 70% evidence |
| Exact sum: 20.2 + 4.3 + 10 + 16.6 = 51.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Snap Inc.SNAP | 48.0/100Mixed-negative evidence61% evidence | TURNING | 21.2/35 Revenue 10.3% · PAT — · OPM change 9.3 pp 62% evidence | 6.3/25 ROCE -1.2% · OPM -4.9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.5/20 RS sector -3.3% · RS bench -13.5% · 1Y -29.9%1 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 6.3 + 10 + 10.5 = 48 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Weibo CorporationWB | 46.0/100Mixed-negative evidence81% evidence | BASING | 13.3/35 Revenue 1.4% · PAT 5.7% · OPM change -1.5 pp 83% evidence | 13.7/25 ROCE 1.9% · OPM 26.3% 76% evidence | 16.3/20 P/E 6.1× · PEG 0.13 65% evidence | 2.7/20 RS sector -26.6% · RS bench -33.9% · 1Y -48.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13.3 + 13.7 + 16.3 + 2.7 = 46 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 14Zillow Group, Inc.ZG | 43.3/100Mixed-negative evidence64% evidence | BASING | 20.9/35 Revenue 16.8% · PAT — · OPM change 6.6 pp 62% evidence | 8.9/25 ROCE 0.8% · OPM 5.1% 76% evidence | 8.7/20 P/E 165.6× · PEG — 15% evidence | 4.8/20 RS sector -33.2% · RS bench -40.8% · 1Y -61.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 20.9 + 8.9 + 8.7 + 4.8 = 43.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Groupon, Inc.GRPN | 41.3/100Thin evidence · provisional58% evidence | TURNING | 11.0/35 Revenue 2.7% · PAT — · OPM change -4.4 pp 62% evidence | 6.3/25 ROCE -1.4% · OPM -2.8% 76% evidence | 9.9/20 P/E 19.2× · PEG — 15% evidence | 14.1/20 RS sector 12.1% · RS bench 1.7% · 1Y -14.2%10 of 12 weeks ahead 70% evidence |
| Exact sum: 11 + 6.3 + 9.9 + 14.1 = 41.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16RUM Group Inc.RUM | 41.2/100Thin evidence · provisional58% evidence | TURNING | 13.0/35 Revenue 1% · PAT — · OPM change -0.1 pp 62% evidence | 3.4/25 ROCE -12.6% · OPM -153.6% 76% evidence | 9.0/20 P/E 47.1× · PEG — 15% evidence | 15.8/20 RS sector 28% · RS bench 16.8% · 1Y 7.9%5 of 12 weeks ahead 70% evidence |
| Exact sum: 13 + 3.4 + 9 + 15.8 = 41.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17WEBTOON Entertainment Inc.WBTN | 40.6/100Thin evidence · provisional55% evidence | BASING | 17.7/35 Revenue 2.2% · PAT — · OPM change 5.7 pp 62% evidence | 7.1/25 ROCE -0.6% · OPM -2.5% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 5.8/20 RS sector -11.7% · RS bench -20.8% · 1Y -51.1%1 of 12 weeks ahead 70% evidence |
| Exact sum: 17.7 + 7.1 + 10 + 5.8 = 40.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18Yelp Inc.YELP | 38.4/100Mixed-negative evidence75% evidence | ASLEEP | 12.8/35 Revenue 2% · PAT -2.1% · OPM change -0.6 pp 83% evidence | 12.6/25 ROCE 3.3% · OPM 7.6% 76% evidence | 8.3/20 P/E 11.3× · PEG 2.14 65% evidence | 4.7/20 RS sector -19% · RS bench -26.8% · 1Y -34.8%1 of 12 weeks ahead 70% evidence |
| Exact sum: 12.8 + 12.6 + 8.3 + 4.7 = 38.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Upwork Inc.UPWK | 37.2/100Mixed-negative evidence65% evidence | TURNING | 10.4/35 Revenue 2.5% · PAT -53.6% · OPM change -3.4 pp 83% evidence | 13.0/25 ROCE 4.2% · OPM 16.7% 76% evidence | 10.4/20 P/E 13.5× · PEG — 15% evidence | 3.4/20 RS sector -33.3% · RS bench -40.8% · 1Y -57.4%1 of 12 weeks ahead 70% evidence |
| Exact sum: 10.4 + 13 + 10.4 + 3.4 = 37.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20StubHub Holdings, Inc.STUB | 34.4/100Thin evidence · provisional55% evidence | ASLEEP | 12.8/35 Revenue -0.8% · PAT — · OPM change -0.9 pp 62% evidence | 8.6/25 ROCE 0.6% · OPM 5.8% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.0/20 RS sector -43.9% · RS bench -50.4% · 1Y -68.1%6 of 12 weeks ahead 70% evidence |
| Exact sum: 12.8 + 8.6 + 10 + 3 = 34.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21Genius Sports LimitedGENI | 33.9/100Thin evidence · provisional55% evidence | TURNING | 13.4/35 Revenue 33.3% · PAT — · OPM change -8.8 pp 62% evidence | 4.3/25 ROCE -5.8% · OPM -23% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.2/20 RS sector -9.5% · RS bench -20% · 1Y -48.2%11 of 12 weeks ahead 70% evidence |
| Exact sum: 13.4 + 4.3 + 10 + 6.2 = 33.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Pinterest, Inc.PINS | 33.5/100Adverse evidence71% evidence | ASLEEP | 11.6/35 Revenue 16.3% · PAT -82.4% · OPM change -3.9 pp 83% evidence | 6.8/25 ROCE -1.8% · OPM -8% 76% evidence | 9.4/20 P/E 38.2× · PEG — 15% evidence | 5.7/20 RS sector -16.2% · RS bench -24.9% · 1Y -47.9%9 of 12 weeks ahead 100% evidence |
| Exact sum: 11.6 + 6.8 + 9.4 + 5.7 = 33.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23People IncorporatedPPLI | 31.0/100Adverse evidence64% evidence | ASLEEP | 9.2/35 Revenue -9.4% · PAT — · OPM change -14.5 pp 62% evidence | 6.8/25 ROCE -0.6% · OPM -9.5% 76% evidence | 8.9/20 P/E 108.2× · PEG — 15% evidence | 6.1/20 RS sector -2.5% · RS bench -10.4% · 1Y 3.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 9.2 + 6.8 + 8.9 + 6.1 = 31 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Trump Media & Technology Group Corp.DJT | 29.1/100Thin evidence · provisional57% evidence | ASLEEP | 7.2/35 Revenue 0% · PAT — · OPM change -28873.5 pp 62% evidence | 5.2/25 ROCE -27.2% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.7/20 RS sector -18.7% · RS bench -27.4% · 1Y -51%3 of 12 weeks ahead 100% evidence |
| Exact sum: 7.2 + 5.2 + 10 + 6.7 = 29.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Opera Limited's stock price today?
Opera Limited trades at $18.4, −2.1% over the past year. The company is valued at $2.0 B. The stock sits at 76% of its 52-week range of $12–$20, +11.6% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 1 weeks in. — as of 17 September 2026.
What were Opera Limited's latest quarterly results?
Opera Limited reported revenue of $0.2 B and net profit of $0.0 B for the Mar 26 quarter. Revenue rose 28.6% and profit rose 0.0% year on year. Earnings per share were $0.27. The operating margin was 16.7%, 2.4 pp higher than a year earlier. — as of 17 September 2026.
What is Opera Limited's revenue?
Opera Limited reported revenue of $0.2 B in the Mar 26 quarter, +28.6% year on year. For the full FY25 fiscal year, revenue was $0.6 B (+27.1%). Over the last 4 years revenue compounded at 25.0% a year. — as of 17 September 2026.
What is Opera Limited's profit?
Opera Limited earned $0.0 B of net profit in the Mar 26 quarter, +0.0% year on year. Full-year FY25 profit was $0.1 B. The operating margin ran 16.7% in the latest quarter. — as of 17 September 2026.
What is Opera Limited's market cap?
Opera Limited's market capitalisation is $2.0 B at a stock price of $18.4. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
What is Opera Limited's P/E ratio?
Opera Limited trades at a P/E of 13.4×, at the 37th percentile of its own 4-year range, against a long-run median of 15.0×. This is a comparison with the stock's own history, not a value call — as of 17 September 2026.
Does Opera Limited pay a dividend?
Yes — Opera Limited declared $0.40 per share for Dec 25, and $2.00 per share across the last four reported quarters. The latest quarter is down 50.0% on the same quarter a year earlier. — as of 17 September 2026.
What is Opera Limited's dividend per share?
Opera Limited's most recently declared dividend is $0.40 per share for Dec 25, giving $2.00 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 17 September 2026.
What is Opera Limited's dividend yield?
Opera Limited's trailing dividend yield is 10.86%: $2.00 declared per share across the last four reported quarters, against a share price of $18.4. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 17 September 2026.
Is Opera Limited overvalued?
On its own history, Opera Limited looks mid-range: its P/E of 13.4× sits at the 37th percentile of its 4-year range (long-run median 15.0×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 17 September 2026.
Is Opera Limited growing?
Yes — Opera Limited is growing: latest-quarter revenue +28.6% year on year, profit +0.0%, and the margin +2.4 pp at 16.7%. The earnings engine currently reads: improving — as of 17 September 2026.
How is Opera Limited performing?
Opera Limited is in a confirmed uptrend, 1 weeks in. Its latest quarter's revenue rose 28.6% and profit rose 0.0% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 3 weeks. This describes what the data did, not a rating. — as of 17 September 2026.
What stage is Opera Limited in?
Turning around — profit growth swung from −43.8% at the trough to +33.3% off a 3-quarter-old trough, ROCE holding at 10.3%. The read comes from the last 12 quarters of growth (revenue growth +25.0% latest, profit growth +33.3% latest, eps growth +34.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 17 September 2026.
Is Opera Limited in an uptrend?
Yes — the price is in a confirmed uptrend (week 1 of stage 2), trading +11.6% versus its 200-day average and at 76% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.
Is Opera Limited beating the market?
Not lately — on a trailing-13-week view Opera Limited is currently behind the S&P 500 (3 weeks and counting; last ahead the week of 2026-08-28), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 8.1 years the stock moved +60% against the S&P 500's +166% — behind the index over the full window. — as of 17 September 2026.
Will Opera Limited's stock price go up?
This page publishes no price forecast for Opera Limited. What it measures instead: the stock price is $18.4, the price is in a confirmed uptrend 1 weeks in. Its P/E of 13.4× sits at the 37th percentile of its own 4-year range. — as of 17 September 2026.
Does Opera Limited have too much debt?
No — Opera Limited's debt-to-equity is 0.01. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. The returns on this page are earned, not borrowed — as of 17 September 2026.
What is Opera Limited's capex?
Opera Limited spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 17 September 2026.
What is Opera Limited's cash flow?
Opera Limited generated $0.1 B of operating cash flow in FY25 and $0.1 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.1 B, so operating cash ran ahead of profit. — as of 17 September 2026.
Is Opera Limited's profit real cash?
Yes — over the last 3 fiscal years, 88% of Opera Limited's reported profit arrived as operating cash. In FY25, operating cash was $0.1 B against reported profit of $0.1 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 17 September 2026.
How financially safe is Opera Limited?
On the balance sheet, the Z-score reads 7.74 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 17 September 2026.
Where is Opera Limited in its business cycle?
Opera Limited's FY25 operating margin was 14.8%, against a 5-year band of −4.0%–18.8%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 16.7%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the Opera Limited story?
The sharpest disagreement: annual EPS moved +32.2% against a −2.1% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is Opera Limited a stock worth studying right now?
This is not investment advice. The machine read: Opera Limited's earnings have outrun its stock. EPS grew +32.2% in a year against a −2.1% price move. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!